Your browser doesn't support javascript.
loading
Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II
The Korean Journal of Internal Medicine ; : 656-667, 2017.
Article in English | WPRIM | ID: wpr-67790
ABSTRACT
BACKGROUND/

AIMS:

We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients.

METHODS:

Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month.

RESULTS:

There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13% ± 1.21% in 4 mg group and –0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively).

CONCLUSIONS:

Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Blood Glucose / Glycated Hemoglobin / Follow-Up Studies / Fasting / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Death / Atherosclerosis / Glucose / Heart Failure / Hospitalization Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: The Korean Journal of Internal Medicine Year: 2017 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Blood Glucose / Glycated Hemoglobin / Follow-Up Studies / Fasting / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Death / Atherosclerosis / Glucose / Heart Failure / Hospitalization Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: The Korean Journal of Internal Medicine Year: 2017 Type: Article